RAD-140 or testosterone for a first cycle?

Testosterone, without hesitation. The human safety corpus is incomparable: decades of RCTs, several clinical guidelines (Bhasin 2018), a well-characterized and manageable side effect profile. RAD-140 has a limited human dossier (phase 1 + preclinical), no long safety RCT, and a concerning signal of transaminase elevation in some users. Start with clean testosterone 400 mg/week × 12 weeks to know your own hormonal response before experimenting with less documented compounds.

Does RAD-140 really suppress testosterone as much as exogenous testosterone?

Comparable but variable. Exogenous testosterone at supraphysiological dose (400 mg/week) suppresses endogenous production 95-100% (collapsed LH/FSH). RAD-140 at 20 mg/d × 8 weeks suppresses 50-80% per user reports and limited phase 1. Practical effect: both require post-cycle PCT, but recovery under RAD-140 is typically faster (4-6 weeks vs 8-12 for testosterone). T total, LH, FSH panel at W4 post-PCT to confirm.

Does RAD-140 cause hepatic toxicity?

Possible but rare in short cycles. Several case reports (DILI under SARMs) suggest ALT/AST elevation in 10-20% of users on 8-week cycles at 20 mg/d. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. Immediate stop if elevation > 3× normal. Not 17α-alkylated toxicity but distinct hepatic aggression pathway.

How much realistic gains with RAD-140?

At 15-20 mg/d × 8 weeks in intermediate user: +4 to +6 kg net lean mass retained at 3 months post-PCT. Strength up +10-15% on main loads. Dry profile (no aromatization, no notable retention). Gains comparable to a moderate testosterone cycle (300 mg/week), with different practical profile (oral vs injectable, no AI, shorter PCT). Visual effect apparent from W2-W3.

Does RAD-140 improve libido?

Variable and often disappointing. Unlike testosterone which completely covers the androgenic function (elevated libido during cycle), RAD-140 suppresses endogenous testosterone without functionally replacing it at the complete androgenic level. Result: many users report mid-cycle libido drop, equivalent to nandrolone 'deca-dick'. Possible compensation by testosterone at moderate dose (200 mg/week) in parallel to cover the androgenic role, or proviron 50 mg/d.

What PCT after RAD-140?

Start 3-4 days after last intake (half-life ~16-20 h). Standard scheme: clomid 50/25/25/25 mg × 4 weeks + nolvadex 40/20/20/20 mg. No hCG needed in SARM solo (testicles are less atrophied than after exogenous testo). T total, LH, FSH panel at W4 and W8 post-PCT. Typically faster recovery than after a testosterone cycle (4-6 wk vs 8-12 wk). If T < 300 ng/dL at W4 post-cycle, extend PCT and reassess.

Why no PCT for RAD-140?

Polemical question. Some SARM-light protocols claim to skip it in short cycles (< 4 weeks at 10 mg/d), arguing that suppression would be modest and spontaneously reversible. In practice, even short cycles generate measurable suppression (30-40% of endogenous T), and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 wk) is negligible compared to hormonal comfort during recovery.

RAD-140 oral or topical?

Oral exclusively in practice. RAD-140 was developed for oral administration with satisfactory bioavailability. Some topical preparations (5 mg gel) circulate on the underground market, without reliable pharmacokinetic data. Topical absorption remains inferior to oral, and the risk of third-party exposure (cutaneous transfer to a partner) remains poorly documented. For coherence with literature and evaluated protocols, stick to oral form.

RAD-140 vs Testosterone: complete comparison (SARM vs reference AAS)

Q: Why no PCT for RAD-140?

Polemical question. Some SARM-light protocols claim to skip it in short cycles (< 4 weeks at 10 mg/d), arguing that suppression would be modest and spontaneously reversible. In practice, even short cycles generate measurable suppression (30-40% of endogenous T), and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 wk) is negligible compared to hormonal comfort during recovery.

Q: RAD-140 oral or topical?

Oral exclusively in practice. RAD-140 was developed for oral administration with satisfactory bioavailability. Some topical preparations (5 mg gel) circulate on the underground market, without reliable pharmacokinetic data. Topical absorption remains inferior to oral, and the risk of third-party exposure (cutaneous transfer to a partner) remains poorly documented. For coherence with literature and evaluated protocols, stick to oral form.

Critère	rad-140	testosterone
Class	Non-steroidal SARM	Steroidal AAS (reference)
Route	Oral	Injectable (cyp/enanthate)
Aromatization	No	Yes (to E2)
Cutaneous androgenic effect	Moderate	Marked
HPG axis suppression	Moderate to strong	Strong
Typical dose	10-20 mg/d	300-600 mg/week
Human studies	Limited phase 1	Multiple RCTs (Bhasin 1996+)
Libido	Variable	Covering

Quand choisir rad-140

RAD-140 (testolone) is a non-steroidal SARM with high affinity to the muscular androgen receptor, with tissue selectivity proven in preclinical (Miller 2010). Choose it for: (1) an oral cycle without injections, (2) a milder cutaneous androgenic profile than testosterone (less acne, less hair loss in non-predisposed), (3) a SARM experience targeted at faster muscular gains than LGD-4033 or ostarine. Pharmacological profile (Solomon 2019, Bhasin 2009): SARM potent in raw anabolic effect, clear muscular selectivity in preclinical, no aromatization so no AI needed, no prostatic 5α-reduction. Drawbacks to anticipate (Pope 2014, Endocrine Society): marked HPG suppression (50-80% at 20 mg/d × 8 weeks), rigorous PCT required, possible transaminase elevation, degraded lipid profile (HDL down), limited human safety corpus (essentially preclinical + phase 1). No long human RCT published to date. Typical dose 10-20 mg/d × 6-8 weeks, single morning intake (half-life ~16-20 h). PCT clomid + nolvadex 4-6 weeks required. Not suited for women (virilization possible) nor adolescents (impact on hormonal maturation).

Quand choisir testosterone

Exogenous testosterone is the absolute reference molecule of androgenic culture: Bhasin 1996 (NEJM, RCT 600 mg/week × 10 weeks, +6.1 kg lean mass), Bhasin 2001 (linear dose-response up to 300 mg/week then plateau), Bhasin 2018 (Endocrine Society TRT guideline). Choose it for: (1) a first cycle where scientific base matters, (2) any cycle aiming at complete androgenic coverage (libido, energy, bone density, male hormonal profile), (3) clinically supervised TRT, (4) the base of any more advanced AAS stack. Pharmacological profile: complete androgen (ratio 100:100), aromatization controllable by dose-dependent AI, half-life variable by ester (enanthate ~4.5 d, cypionate ~8 d theoretical, propionate ~2 d). Drawbacks: injections required (1-2× per week for long ester, 3× for propionate), aromatization to manage actively, marked androgenic profile (possible acne and hair loss in predisposed), complete and dose-dependent HPG suppression. But no compound has a more solid safety corpus. For advanced users, dose 400-600 mg/week in 12-16 wk cycle. For TRT, 100-150 mg/week.

Combinaison ?

The RAD-140 + testosterone combo is widespread but without clear benefit: testosterone at 300-500 mg/week already strongly occupies the muscular androgen receptor, and adding RAD-140 only cumulates suppression without significantly additive anabolic gains. If still combined, scheme: testosterone 300 mg/week + RAD-140 10 mg/d × 8 weeks, followed by classic PCT 4-6 weeks. More useful: RAD-140 as oral kickstart in place of dianabol for a 'cleaner' cycle: RAD-140 15 mg/d × 6 weeks at cycle start of testosterone, with testo-alone bridge to 500 mg/week thereafter. Advantages: less water retention than a dianabol kickstart, milder cutaneous androgenic profile than dianabol or anadrol, no aromatization to manage for RAD-140 (AI remains useful for the testo base). Monitoring: T total and free, LH, FSH, ALT/AST, complete lipids, E2 at W0, W6, W12. PCT clomid + nolvadex 4-6 weeks after last dose (start 2-3 weeks after last testo injection). Cardiovascular and hepatic monitoring specific to both compounds, with particular attention to hepatic function under RAD-140 (DILI signal). Sample 12-week hybrid timeline: W0 baseline complete panel, W1-W6 RAD-140 15 mg/d as kickstart + testo enanthate 500 mg/week, W2 first BP and ALT/AST check (RAD-140 hepatic signal), W4 measured E2 and AI titration, W6 mid-cycle full panel, W6 RAD-140 stop, W7-W12 testo solo continuation, W12 last testo injection, W14 PCT start (testo-timed at 14 days), W22 post-PCT recovery confirmation. The hybrid is favored over RAD-140 + full-dose testo because the RAD-140 kickstart accelerates onset while sparing peak supraphysiological exposure. Lab testing for RAD-140 authenticity: underground market mislabeling rate 40-60% per independent analyses — verify product with Janoshik or similar lab before starting cycle.

FAQ

RAD-140 or testosterone for a first cycle?: Testosterone, without hesitation. The human safety corpus is incomparable: decades of RCTs, several clinical guidelines (Bhasin 2018), a well-characterized and manageable side effect profile. RAD-140 has a limited human dossier (phase 1 + preclinical), no long safety RCT, and a concerning signal of transaminase elevation in some users. Start with clean testosterone 400 mg/week × 12 weeks to know your own hormonal response before experimenting with less documented compounds.
Does RAD-140 really suppress testosterone as much as exogenous testosterone?: Comparable but variable. Exogenous testosterone at supraphysiological dose (400 mg/week) suppresses endogenous production 95-100% (collapsed LH/FSH). RAD-140 at 20 mg/d × 8 weeks suppresses 50-80% per user reports and limited phase 1. Practical effect: both require post-cycle PCT, but recovery under RAD-140 is typically faster (4-6 weeks vs 8-12 for testosterone). T total, LH, FSH panel at W4 post-PCT to confirm.
Does RAD-140 cause hepatic toxicity?: Possible but rare in short cycles. Several case reports (DILI under SARMs) suggest ALT/AST elevation in 10-20% of users on 8-week cycles at 20 mg/d. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. Immediate stop if elevation > 3× normal. Not 17α-alkylated toxicity but distinct hepatic aggression pathway.
How much realistic gains with RAD-140?: At 15-20 mg/d × 8 weeks in intermediate user: +4 to +6 kg net lean mass retained at 3 months post-PCT. Strength up +10-15% on main loads. Dry profile (no aromatization, no notable retention). Gains comparable to a moderate testosterone cycle (300 mg/week), with different practical profile (oral vs injectable, no AI, shorter PCT). Visual effect apparent from W2-W3.
Does RAD-140 improve libido?: Variable and often disappointing. Unlike testosterone which completely covers the androgenic function (elevated libido during cycle), RAD-140 suppresses endogenous testosterone without functionally replacing it at the complete androgenic level. Result: many users report mid-cycle libido drop, equivalent to nandrolone 'deca-dick'. Possible compensation by testosterone at moderate dose (200 mg/week) in parallel to cover the androgenic role, or proviron 50 mg/d.
What PCT after RAD-140?: Start 3-4 days after last intake (half-life ~16-20 h). Standard scheme: clomid 50/25/25/25 mg × 4 weeks + nolvadex 40/20/20/20 mg. No hCG needed in SARM solo (testicles are less atrophied than after exogenous testo). T total, LH, FSH panel at W4 and W8 post-PCT. Typically faster recovery than after a testosterone cycle (4-6 wk vs 8-12 wk). If T < 300 ng/dL at W4 post-cycle, extend PCT and reassess.
Why no PCT for RAD-140?: Polemical question. Some SARM-light protocols claim to skip it in short cycles (< 4 weeks at 10 mg/d), arguing that suppression would be modest and spontaneously reversible. In practice, even short cycles generate measurable suppression (30-40% of endogenous T), and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 wk) is negligible compared to hormonal comfort during recovery.
RAD-140 oral or topical?: Oral exclusively in practice. RAD-140 was developed for oral administration with satisfactory bioavailability. Some topical preparations (5 mg gel) circulate on the underground market, without reliable pharmacokinetic data. Topical absorption remains inferior to oral, and the risk of third-party exposure (cutaneous transfer to a partner) remains poorly documented. For coherence with literature and evaluated protocols, stick to oral form.

RAD-140 vs Testosterone: complete comparison (SARM vs reference AAS)

Critère	rad-140	testosterone
Class	Non-steroidal SARM	Steroidal AAS (reference)
Route	Oral	Injectable (cyp/enanthate)
Aromatization	No	Yes (to E2)
Cutaneous androgenic effect	Moderate	Marked
HPG axis suppression	Moderate to strong	Strong
Typical dose	10-20 mg/d	300-600 mg/week
Human studies	Limited phase 1	Multiple RCTs (Bhasin 1996+)
Libido	Variable	Covering

Quand choisir rad-140

Quand choisir testosterone

Combinaison ?

FAQ

RAD-140 or testosterone for a first cycle?: Testosterone, without hesitation. The human safety corpus is incomparable: decades of RCTs, several clinical guidelines (Bhasin 2018), a well-characterized and manageable side effect profile. RAD-140 has a limited human dossier (phase 1 + preclinical), no long safety RCT, and a concerning signal of transaminase elevation in some users. Start with clean testosterone 400 mg/week × 12 weeks to know your own hormonal response before experimenting with less documented compounds.
Does RAD-140 really suppress testosterone as much as exogenous testosterone?: Comparable but variable. Exogenous testosterone at supraphysiological dose (400 mg/week) suppresses endogenous production 95-100% (collapsed LH/FSH). RAD-140 at 20 mg/d × 8 weeks suppresses 50-80% per user reports and limited phase 1. Practical effect: both require post-cycle PCT, but recovery under RAD-140 is typically faster (4-6 weeks vs 8-12 for testosterone). T total, LH, FSH panel at W4 post-PCT to confirm.
Does RAD-140 cause hepatic toxicity?: Possible but rare in short cycles. Several case reports (DILI under SARMs) suggest ALT/AST elevation in 10-20% of users on 8-week cycles at 20 mg/d. Mechanism: hepatic metabolism of the compound that can induce drug-induced hepatitis in predisposed subjects or under products of variable purity. ALT/AST monitoring at W0, W4, W8 essential. Immediate stop if elevation > 3× normal. Not 17α-alkylated toxicity but distinct hepatic aggression pathway.
How much realistic gains with RAD-140?: At 15-20 mg/d × 8 weeks in intermediate user: +4 to +6 kg net lean mass retained at 3 months post-PCT. Strength up +10-15% on main loads. Dry profile (no aromatization, no notable retention). Gains comparable to a moderate testosterone cycle (300 mg/week), with different practical profile (oral vs injectable, no AI, shorter PCT). Visual effect apparent from W2-W3.
Does RAD-140 improve libido?: Variable and often disappointing. Unlike testosterone which completely covers the androgenic function (elevated libido during cycle), RAD-140 suppresses endogenous testosterone without functionally replacing it at the complete androgenic level. Result: many users report mid-cycle libido drop, equivalent to nandrolone 'deca-dick'. Possible compensation by testosterone at moderate dose (200 mg/week) in parallel to cover the androgenic role, or proviron 50 mg/d.
What PCT after RAD-140?: Start 3-4 days after last intake (half-life ~16-20 h). Standard scheme: clomid 50/25/25/25 mg × 4 weeks + nolvadex 40/20/20/20 mg. No hCG needed in SARM solo (testicles are less atrophied than after exogenous testo). T total, LH, FSH panel at W4 and W8 post-PCT. Typically faster recovery than after a testosterone cycle (4-6 wk vs 8-12 wk). If T < 300 ng/dL at W4 post-cycle, extend PCT and reassess.
Why no PCT for RAD-140?: Polemical question. Some SARM-light protocols claim to skip it in short cycles (< 4 weeks at 10 mg/d), arguing that suppression would be modest and spontaneously reversible. In practice, even short cycles generate measurable suppression (30-40% of endogenous T), and recovery without pharmacological support takes 8-12 weeks vs 4-6 with PCT. The cost of a PCT (nolvadex 20 € for 4 wk) is negligible compared to hormonal comfort during recovery.
RAD-140 oral or topical?: Oral exclusively in practice. RAD-140 was developed for oral administration with satisfactory bioavailability. Some topical preparations (5 mg gel) circulate on the underground market, without reliable pharmacokinetic data. Topical absorption remains inferior to oral, and the risk of third-party exposure (cutaneous transfer to a partner) remains poorly documented. For coherence with literature and evaluated protocols, stick to oral form.